ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag tuberculosis pharma fda genetics genomics

Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Updated July 9
Track COVID-19 Vaccines Advancing Through Clinical Trials
The Scientist | Apr 7, 2020 | 10+ min read
Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Overcoming Resistance
The Scientist | Apr 1, 2014 | 10+ min read
In the face of bacterial threats that can evade modern medicines, researchers are trying every trick in the book to develop new, effective antibiotics.
Malaria, Science, and Social Responsibility
Bennett Daviss(bdaviss@the-scientist.com) | Mar 27, 2005 | 6 min read
A problem that has seemed intractable for decades may finally be cracking: How to create affordable drug therapies for people who don't offer pharmaceutical companies a commercial market?
Mining the Ubiquitin Pathway
John Hall(hall@lifesensors.com) | Dec 4, 2005 | 5 min read
In October 2004, the Royal Swedish Academy of Sciences awarded the Nobel Prize in Chemistry to Aaron Ciechanover, Avram Hersko, and Irwin Rose "for the discovery of ubiquitin-mediated protein degradation."
Bioterrorism Research: New Money, New Anxieties
John Dudley Miller | Apr 6, 2003 | 8 min read
Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th
Nanoscience is Out of the Bottle
Jeffrey Perkel | Jul 27, 2003 | 10+ min read
 SUPER GOO: Nanotech and Super Heroes? It's a natural. A nanoscale adhesive, developed by University of Manchester researchers, lets this Spiderman hang with confidence. (Reprinted with permission from Nature Materials, 2:461-63, 2003) Don't look now, but the nanotech revolution is already here. It began as a collection of curiosities: nano-enabled sunscreens, tennis racquets, fishing rods, and stain-resistant pants. And more are coming. Nanotech supporters say the technology will benef

Run a Search

ADVERTISEMENT